Retrophin Inc (RTRX) : Perceptive Advisors scooped up 280,000 additional shares in Retrophin Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 3,279,380 shares of Retrophin Inc which is valued at $56,831,655.Retrophin Inc makes up approximately 4.16% of Perceptive Advisors’s portfolio.
Other Hedge Funds, Including , Analytic Investors sold out all of its stake in RTRX during the most recent quarter. The investment firm sold 93,756 shares of RTRX which is valued $1,624,791.Ubs Asset Management Americas Inc boosted its stake in RTRX in the latest quarter, The investment management firm added 8,100 additional shares and now holds a total of 19,500 shares of Retrophin Inc which is valued at $340,275.Gsa Capital Partners Llp boosted its stake in RTRX in the latest quarter, The investment management firm added 18,920 additional shares and now holds a total of 46,509 shares of Retrophin Inc which is valued at $879,485. Retrophin Inc makes up approx 0.05% of Gsa Capital Partners Llp’s portfolio. Quantitative Investment Management sold out all of its stake in RTRX during the most recent quarter. The investment firm sold 15,200 shares of RTRX which is valued $283,328. Pyrrho Capital Management Lp sold out all of its stake in RTRX during the most recent quarter. The investment firm sold 67,820 shares of RTRX which is valued $1,247,888.
Retrophin Inc closed down -0.1 points or -0.59% at $16.98 with 2,81,477 shares getting traded on Tuesday. Post opening the session at $17.13, the shares hit an intraday low of $16.97 and an intraday high of $17.25 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Retrophin Inc reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.18 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.11. The company had revenue of $33.30 million for the quarter, compared to analysts expectations of $32.69 million. The company’s revenue was up 38.2% compared to the same quarter last year.
Retrophin Inc. (Retrophin) is a biopharmaceutical company. The Company is focused on the discovery acquisition development and commercialization of drugs for the treatment of debilitating and life-threatening diseases. The Company is focused on various catastrophic diseases affecting children including focal segmental glomerulosclerosis (FSGS) and pantothenate kinase-associated neurodegeneration (PKAN). The Company is engaged in enrolling patients in a Phase II clinical trial for its lead compound Sparsentan for FSGS. The Company’s products include Thiola (Tiopronin) and Chenodal. Its Thiola is used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Chenodal is a tablet of chenodiol (chenodeoxycholic acid). Its other products include RE-024 and RE-034 which are in pre-clinical stage.